In a quest to expand its rare disease pipeline, Clementia, a subsidiary of Ipsen, has entered into an agreement with Blueprint Medicines for up to US$535 M to develop BLU-782, an investigational ALK2 inhibitor for the treatment of fibrodysplasia ossificans progressiva (FOP). BLU-782 is expected to complement Ipsen’s current FOP drug in its pipeline, palovarotene, which Ipsen gained after its acquisition of Clementia in April 2019. Regulatory approval for palovaroteneis expected in 2020.